Coya Therapeutics gains on positive ALS therapy data

Coya Therapeutics

21/03/2023 14:08

** Drug developer Coya Therapeutics Inc's shares  COYA.O 
rise 4.95% to $4.2 
    ** Reports positive data from an initial proof-of-concept
clinical study for its experimental biologic therapy, COYA 302,
for amyotrophic lateral sclerosis (ALS), a rare neurological
disease
    ** Study tested COYA 302's early efficacy using a validated
rating tool for monitoring the progression of disability in 4
ALS patients 
    ** Says therapy appeared to be well-tolerated and indicated
significant amelioration in disease progression based on
statistically similar scores 
    ** No patient discontinued the study, and no deaths or other
serious adverse events were reported
    ** Study also tested safety and tolerability, function of
regulatory T cells, and some biomarkers
    ** COYA plans to file clinical trial application with the
U.S. FDA in H1 of 2023 and initiate a study soon thereafter 
    ** Including session's gain, stock down 10.5% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))